Patents by Inventor Torsten Tonn

Torsten Tonn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAR-expressing NK-92 cells as cell therapeutic agents
    Patent number: 10550197
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20180282427
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErhB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying au ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 4, 2018
    Applicants: CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS, DRK BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • Car-expressing NK-92 cells as cell therapeutic agents
    Patent number: 9920132
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 20, 2018
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK Blutspendedienst Baden-Wurttemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20170283507
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: May 19, 2017
    Publication date: October 5, 2017
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20170129967
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 11, 2017
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • Expression of proteins in cord blood-derived endothelial cells
    Publication number: 20060034813
    Abstract: The invention provides a population of mature endothelial cells derived from human cord blood. The cells can be transduced with DNA encoding a therapeutically effective protein such as a blood coagulation factor. The cells are useful in a method for the production of a blood coagulation factor. They can further be used in hemophilia A or B gene therapy.
    Type: Application
    Filed: October 6, 2005
    Publication date: February 16, 2006
    Inventors: Christian Herder, Torsten Tonn, Manuel Grez, Erhard Seifried